Across TCGA pan-cancer cohorts, ENTPD8 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ENTPD8 data layer compared with 28 for mass-spec protein.
The strongest signal is observed in sarcoma (SARC), where higher ENTPD8 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ENTPD8 expression acts as an unfavorable survival marker.
SARC, UCEC, and SKCM are the cancer types where ENTPD8 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.